Similar results were obtained for the effect of NPM1-A versus NPM1-RA on OS and RFS in patients receiving chemotherapy only (without allogeneic transplantation in first CR), patients with de novo AML and patients <60 or ≥60 years (text and Figures S3, S4 and S5 in File S1). The gene discussed is NPM1; the disease is acute myeloid leukemia.